Company Presentation

AI SummaryClose X

Coiled Therapeutics plc has announced that its investor presentation for the Proactive One2One Investor Forum is available for download on their website, ahead of their presentation today. The company, an AIM-listed clinical-stage oncology firm developing precision medicines, is focused on its lead program AO-252, a TACC3 inhibitor currently in Phase I clinical trials in the USA for hard-to-treat cancers, with plans to initiate dose-expansion cohorts in prostate and ovarian cancer during 2026.

Disclaimer*

UK 100

Latest directors dealings